Alstem
Private Company
Funding information not available
Overview
Alstem operates as a specialized contract research organization (CRO) and service provider in the cell engineering space, offering a suite of technical services centered on iPSC technology, gene editing, and viral vector production. The company positions itself as an enabler for research institutions and drug developers, providing the custom cellular tools and models necessary for advanced discovery and preclinical work. Its business model is based on fee-for-service work, with a focus on fast turnaround times and guaranteed quality. While not developing its own therapeutic pipeline, Alstem's platform supports critical early-stage research across multiple therapeutic areas, including neuroscience, oncology, and regenerative medicine.
Technology Platform
Integrated suite of cell engineering services including iPSC reprogramming, CRISPR/Cas9 gene editing, lentiviral/retroviral packaging, stable cell line generation, cell immortalization, and integration of protein-tagging technologies (HiBiT, HaloTag, NanoLuc).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Alstem competes in the fragmented life science CRO and research tools market. Direct competitors include other specialized iPSC/gene editing service providers (e.g., Applied StemCell, Thermo Fisher's GeneArt services, academic core facilities). It also faces indirect competition from large, full-service CROs that offer cell biology capabilities and from biotech companies that build these capabilities in-house. Its partnership with Promega offers a point of differentiation.